Colorectal Cancer Conference 2025 Colorectal Cancer Conference 2025 - 1/23/2025

January 23, 2025 - 7:00 AM

Online

Overall Activity Objectives:

1 Utilize current practice guidelines for colorectal disease management.

2 Analyze and interpret colorectal cancer procedures and methods.

3 Utilize the changing care models for diagnosis and management of various cancer syndromes. 4 Implement new approaches to screening and preventing colorectal cancers, highlighting the evidence-base for new diagnostics, devices and pharmaceuticals.

5 Employ appropriate surgical approaches to colorectal cancer syndromes for both treatment and prophylaxis, and describe patient factors that guide surgical decision-making.

6 Predict prognosis and outcomes for colorectal cancer patients.

7 Identify best candidates for specific treatment based on accurate diagnosis and multidisciplinary discussion.

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Philip Rosen, MD	Faculty, Planning Committee Member	Nothing to disclose - 11/07/2024
Meghan L Good, MD	Activity Director, Faculty	Nothing to disclose - 12/17/2024
Aaron James Scott, MD	Faculty	Advisor-Exelixis, Inc. (Relationship has ended) Advisor-Pfizer (Any division) (Relationship has ended) Advisor- Bristol-Myers Squibb Company (Relationship has ended) Advisor-Eisai,

Inc. (Relationship has ended) - 08/28/2024

